Intervention
leucovorin
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 8 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownA Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid TumorsNCT07277270 · 2025-12-03
RECRUITINGMOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsNCT06586515 · 2024-09-12
RECRUITINGA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.NCT05355701 · 2022-07-05
ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)NCT04210115 · 2020-02-28
COMPLETEDQUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsNCT03169738 · 2018-02-01
WITHDRAWNCombination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsNCT00227617 · 2005-06-08
TERMINATEDPhase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid TumorsNCT00044785 · 2002-08-01
TERMINATEDA Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast CancerNCT00001498 · 1996-02-01
COMPLETEDCommon conditions
Non-small Cell Lung Cancer2Advanced Colorectal Cancer (Part 1)1Breast Cancer1Breast Neoplasms1Colorectal Cancer1Esophageal Adenocarcinoma (EAC)1Esophageal Squamous Cell Carcinoma (ESCC)1Gastroesophageal Junction Carcinoma (GEJC)1Gastrointestinal Carcinoid Tumor1Glioma1Islet Cell Tumor1Lung Cancer1Melanoma1Neoplasms1Neoplastic Syndrome1Neuroendocrine Tumor1Non-Small-Cell Lung Cancer1Pancreatic Ductal Adenocarcinoma1Solid Tumors1Thyroid Cancer1
Leading sponsors
Trial status mix
COMPLETED2
RECRUITING2
TERMINATED2
ACTIVE_NOT_RECRUITING1
WITHDRAWN1
Phase mix
PHASE15
PHASE23
PHASE32
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.